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Summary 
We have cloned a novel mouse CC chemokine cDNA from the lung during an allergic inflam- 
matory reaction. The protein encoded by this cDNA is chemotactic for eosinophils, mono- 
cytes, and lymphocytes in vitro and in vivo. Based on its similarities  in sequence and function 
with  other  CC  chemokines,  we  have  named  it  mouse  monocyte  chemotactic  protein-5 
(mMCP-5). Under noninflammatory conditions, expression of mMCP-5 in the lymph nodes 
and thymus is constitutive and is generally restricted to stromal cells. Neutralization ofmMCP-5 
protein with specific antibodies during an allergic inflammatory reaction in vivo resulted in a 
reduction in the  number of eosinophils that accumulated in the lung.  Moreover, mMCP-5 
mtkNA expression in vivo is regulated differently from that of other major CC chemokines in 
the lung during the allergic reaction, including Eotaxin. The presence oflymphocytes is essen- 
tial for expression of mMCP-5 by alveolar macrophages and smooth muscle cells in the lung, 
and the induction of mMCP-5  RNA  occurs earlier than that of the  eosinophil chemokine 
Eotaxin during allergic inflammation. In contrast to Eotaxin, mR.NA for mMCP-5 can be pro- 
duced by mast cells. From these results,  we postulate that mMCP-5 plays a pivotal role during 
the early stages of allergic lung inflammation. 
T 
he late phase of an asthmatic reaction is mediated by a 
swarm of leukocytes that are recruited to the lung by 
cytokines and  chemotactic factors  (1).  The mechanism(s) 
by which  the  different populations  of leukocytes are  re- 
cruited and how they regulate the attraction and function 
of other  leukocytes  present  at  the  inflammatory  site  is 
poorly understood. However, there is evidence to suggest 
that the accumulation of eosinophils at sites of allergic reac- 
tions may be directly associated with the presence of lym- 
phocytes and with the production by T  cells of cytokines, 
which are known to stimulate eosinophil maturation, acti- 
vation, and survival, or to modulate the expression of adhe- 
sion molecules (2, 3). 
At the present time, the accepted paradigm for leukocyte 
extravasation is that the selective homing of particular cir- 
culating leukocytes into inflamed tissues takes place via the 
generation  of chemotactic gradients  created by chemoat- 
tractants or by specific cytokines termed chemokines (4, 5). 
Most chemokines can be grouped as members of either the 
CXC  (or) or CC  (13) family to denote the  spacing of the 
first two cysteine residues  of the mature proteins. The CXC 
chemokine family seems  to  act  preferentially on  neutro- 
phils and includes, among others, platelet factor 4, NAP-l/ 
IL-8, gro,  IP-10,  and ENA-78.  The CC  family has  been 
described  as  attracting  several leukocyte subsets,  but  not 
neutrophils,  and includes macrophage inflammatory protein 
(MIP)I-loL, -[3, monocyte chemotactic protein-1 (MCP-1)/JE, 
MCP-2,  MCP-3,  Eotaxin,  and RANTES  (6).  The rele- 
vance of chemokines in the migration of leukocytes to in- 
flammatory sites in vivo has been demonstrated in various 
experimental systems of differing complexity (7-9). 
Because  of their  broad  chemotactic  specificities,  CC 
chemokines could play a central role in the  development 
and maintenance of the leukocytic infiltration found in the 
lung  during  allergic  inflammation  (eosinophils,  lympho- 
cytes, monocytes, etc., and lack of a significant and/or pre- 
dominant infiltration of neutrophils). We and others have 
1Abbreviations used in this paper: BMCMC, bone marrow-cultured mast 
cells; h, human; m, mouse; MCP, monocyte  chemotactic  protein; MIP, 
macrophage inflammatory  protein; tkT, reverse  transcnptase. 
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mouse  Eotaxin,  in  the  lungs  of mice  that  were  rendered 
eosinophilic  by  repeated  exposure  to  aerosolized  OVA 
(10--13). 
The work reported here represents our continued efforts 
in  the  identification  and  study  of  CC  chemokines  that 
could be integral in promoting the complex leukocyte in- 
filtration that is present in the lung during allergic reactions. 
We have isolated a novel cDNA from mouse hypereosino- 
philic lungs by PC1L amplification based on consensus se- 
quences  that  are  present  in  CC  chemokine  genes.  This 
novel  mouse  CC  chemokine  has  strong  homology  with 
human  (h)MCP-1.  The chemotactic activity of the protein 
encoded by this gene in vitro, as well as after in vivo ad- 
ministration, and the regulation of the expression and func- 
tion of this gene during lung eosinophilia are presented here. 
Materials  and Methods 
Mice and In  Vivo Procedures.  8-10-wk-old male  and  female 
C57BL/6J and RAG-l-deficient mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME), and kept in the Center for 
Blood Research Specific Pathogen Free mouse facihty (Harvard 
Medical School).  CD3e-transgenic mice  (14)  were kindly pro- 
vided by Dr.  C.  Terhorst  (Beth  Israel Hospital, Boston,  MA). 
OVA-induced  pulmonary  eosinophilia  (Sigma  Immunochemi- 
cals, St. Louis, MO) was generated in these mice (three individual 
experiments, n =  10) as previously described (10). 
Peritoneal recruitment assays in vivo with mouse (m)MCP-5 
protein were performed after injection of 400  or 800  Ixl i.p. of 
mMCP-5  recombinant  protein-containing  conditioned  media 
(see  below)  or  control  conditioned  media.  At  different  time 
points after injection (0, 1, 2, 3, or 4 h), (three individual experi- 
ments,  n  =  8-13 for test and control mice per time point and 
dose), leukocytes recovered from peritoneal lavage were analyzed 
and enumerated.  For the coinjection experiments, bacterial rm- 
Eotaxin (0.5 &g/200 Ixl per mouse; Peprotech, Inc., Rocky Hill, 
NJ) was administered lntraperitoneally simultaneously with either 
400 or 800 Ixl ofmMCP-5 containing conditioned media. In one 
series of experiments, lower doses  of Eotaxxn  (0.2  Ixg/mouse) 
were coinjected with lower doses of mMCP-5  (100  Ixl/mouse). 
Control mice were injected intrapentoneally with (a) rmEotaxin 
protein and control conditioned media; (b) PBS and mMCP-5-con- 
taining conditioned media; and (c) PBS and control conditioned 
media.  All doses  and  volumes were  exactly the  same  as  those 
given to test mice. At different time points after coinjection of 
mMCP-5-containing conditioned media and rmEotaxm (1, 2, 3, 
or 4 h; three individual experiments, n =  4-12, for test and con- 
trol mice per time point and dose), recovered cells from the peri- 
toneum  were  analyzed.  In one  series  of blocking experiments, 
mxce were injected with affinity-pufffied neutralizing polyclonal 
antibodies against mMCP-5  (20  p,g/mouse, i.v.) 30 rain before 
OVA administration on days 20 and 21, and then analyzed 3 h af- 
ter allergen challenge on day 21. OVA-treated control mice were 
rejected with the same amount of control Ab (purified rabbxt Ig 
fraction; Dako Corp., Carpinteria, CA) at the time points indi- 
cated during treatment. 
Cloning of cDNA by Reverse Transcription (RT)-PCR.  A partial 
cDNA fragment of the mMCP-5  gene was cloned from RNA 
extracted from eosinophflic lungs of OVA-sensitized mice (10). 
To  clone the full-length mouse mMCP-5  cDNA, we followed 
the same two-step PCR  amplification strategy that we used re- 
cendy to clone mouse Eotaxin (10). Specific primers used for ev- 
ery step during the cloning were as follows: first step round 1, 5' 
primer 1 (a chimeric primer containing (dT)l  v and sequence of 
the  T7  promoter:  5'-TAATACGACTCACTATAGGGATTTT- 
TTTTTTTTTTTTT)  and 3'  primer (5'-CTCCTTATCCAG- 
TATGGTCC); first step round 2,  5' primer 2  (sequence of the 
T 7 promoter: 5'-TAATACGACTCACTATAGGG) and 3' pnmer 
(designed  nested  to  first  3'-pffmer  from  the  sequence  of the 
cloned  fragment:  5'-ACAGCTTCCCGGGGACACTG);  sec- 
ond step round 1, primers 1 and gene specific 5' primer (designed 
from  the  5'  sequence  of the  cloned  fragment:  5'-AGAGA- 
CACTGGTTCCTGAC);  second step round 2,  primers 2 and a 
second  gene  specific  primer  (a  primer  containing  sequences 
nested to first 5' primer: 5'-TCTCCCTCCACCATGCAGAG). 
Production of Recombinant mMCP-5 Protein in p3X63  Myeloma 
Cells.  The entire coding sequence (from 30 to 450 in the nucle- 
otide sequence) of mMCP-5 cDNA was cloned into the expres- 
sion vector pEFpuro  in  the  sense  or antisense orientation and 
transfected into p3X63 myeloma cells as before (10). To partially 
purify mMCP-5 from the tissue culture conditioned media (15), 
20 ml of mMCP-5-containing or control conditioned media was 
applied to a  1-ml Hepaffn column  (Pharmacla Fine Chemicals, 
Piscataway, NJ), as recommended by supplier. The eluate was ap- 
plied to  a  cation  exchange  column  (mono  S;  Pharmacia)  and 
eluted with a linear gradient from 0 to 1 M  NaC1 in 50 mM ace- 
tate buffer, pH 5.0.  This eluate was diluted 2.5  times and then 
used for the assays shown in Fig. 2 A  (indicated as H.C.). Endo- 
toxin levels were  estimated less  than  0.1  ng/btg  (or  75  U)  of 
MCP-5, as assessed by the LAL assay (BioWhittaker, Inc., Walk- 
ersville, MD). 
In  Vitro Chemotaxis.  The in vitro migration of leukocytes to 
recombinant mMCP-5 was evaluated, in duplicate, using a 24-well 
transwell chamber with a 5-1xm pore (Costar, Cambridge, MA), 
as described previously (10).  For neutralization experiments, 1 or 
10 p.g/ml of affinity-purified anta-nuMCP-5 polyclonal annbod- 
xes were preincubated with mMCP-5-containing or control con- 
ditioned media for 15 min at 37°C and then used for eoslnophil 
chemotaxis as described above. Purified rabbit Ig fraction (Dako) 
was used as a control in this assay. After incubation, the transwells 
were removed and the number of cells per well counted in the 
FACScan  ® (Becton Dickinson &  Co., Mountain View, CA) by 
passing each sample for a constant predetermined time period. A 
constant gate was assigned for each leukocyte subpopulation in 
the  SSC/FSC window  and  was  used  for  every sample.  When 
necessary,  samples  were  also  stained  for  cell  lineage-specific 
markers, and were analyzed as explained below. The chemotactic 
index was calculated as the number of cells that migrated to the 
sample divided by the number of cells that migrated to the nega- 
tive control (control conditioned media). 
Eosinophils were purified from the peritoneum of IL-5-trans- 
genic mice as described previously (10). Monocytes/macrophages 
and neutrophils were obtained from the bone marrow or perito- 
neum after injection of thioglycoUate and percoll gradient separa- 
tion (15). Lymphocytes were obtained from the peripheral blood, 
spleen, LN, or bone marrow after erythrocyte lysis and immuno- 
magnetic  depletion  of Mac-1 ÷  and  Gr-1 +  cells,  as  explained 
above. 
Flow cytometry was performed to determine the cell lineage of 
migratory cells in selected experiments. The migratory cells from the 
assay were incubated with anti-Fc receptor mAb  (2.492;  Phar- 
Mingen), and were then stained with each one of  the following an- 
tibo&es individually: Gr-1 (8C5), Mac-1 (CD1 lb), B220 (CD45R), 
1940  mMCP-5 in Lung Allergic Inflammation IgM, or Thyl.2, conjugated with FITC or PE (PharMingen, San 
Diego, CA). Dead cells were excluded by propidium iodide (Sigma) 
incorporation. Flow cytometry data were acquired with a FACScan  ® 
cytometer, and were analyzed with CELLQUEST software. 
Generation  and  Screening of  Polyclonal Sera and  mAbs  Anti- 
mMCP-5.  Polyclonal sera against mMCP-5  was generated ac- 
cording to standard methods using the synthetic peptide CADP- 
KEKWVKNSINHLDKTS,  covering amino acids 52-71  in the 
mMCP-5  peptide sequence,  coupled to KLH (Pierce Chemical 
Co., Rockford, IL; 17). Rabbit serum was first depleted of anti- 
mouse IgG antibodies by passage over a mouse IgG column, and 
anti-mMCP-5 antibodies were purified from the flowthrough on 
a mMCP-5 peptide (52-71) affinity column. Antibody titers were 
determined by ELISA. 
10-wk-old Wistar rats were immunized in the hind footpad 
with the KLH-coupled mMCP-5 peptide, and cell fusions were 
performed as  described before  (18).  Positive supematants  were 
studied in Western blot analysis  against mMCP-5  that was pro- 
duced by transfected cells. A  total of nine mAbs were obtained 
and characterized by Western blotting and immunostaining. Four 
mAbs recognized mMCP-5 epitopes that were present in frozen 
sections. One of those, ZY2A11,  was used for the experiments 
described here. 
Affinity-purified rabbit  polyclonal antibodies  and  rat  mAbs 
were shown to recognize a specific band in a Western blot against 
mMCP-5---containing  conditioned  media,  but  not  against  the 
conditioned media of mock-transfected cells (data not shown). 
This  band  was  specifically competed by  preincubation the  Ab 
preparations with the mMCP-5  (52-71) peptide used for immu- 
nization (data not shown). 
Southern and Northern Blots.  Both were  performed following 
standard methods and the following probes: mMCP-5  (0.29-kb 
fragment cloned from 5' RACE), Eotaxin (10),  RANTES (19), 
and MIP-let (20). 
Measurement of mMCP-5  and  mEotaxin  mRNA  Expression by 
RT-PCR.  For RT-PCR,  we followed the methods described 
before (10).  The specific primers for mMCP-5 used in PCR are 
as  following:  5'  primer,  5'-TCTCCCTCCACCATGCAGAG 
and 3' primer, 5'-CTCCTTATCCAGTATGGTCC. 
The macrophage cell lines RAW287 and P388D1  were cul- 
tured with TNF-et (20 ng/ml) for 24 h, and the endothelial cell 
line bEnd3  and the  fibroblast cell line NIH3T3  were  cultured 
with  PMA/Ionomycin  (10:500  ng/ml)  for  8  h.  Macrophages 
were freshly isolated from mouse peritoneal cavity 48 h after in- 
jection ofthioglycollate (1 ml/mouse), and were cultured in vitro 
with TNF-ot (20 ng/rrd) or IFN-~/respectively  for 24 h. 
The mast cells studied include a cloned, growth factor-inde- 
pendent mast cell hne (C1.MC/C57.1  [21]) or primary cultures of 
bone marrow-cultured mast cells (BMCMC). Primary cultures of 
BMCMC were generated from bone marrow cells isolated from 
BALB/c mice as described previously (21).  BMCMC were used 
for experiments at 4-6 wk, at which time mast cells represented 
>99% of the cells, as determined by neutral red staining. 
Immunohistochemical Phenotyping and  Quantitation of Leukocytes. 
The  number  and  type  of leukocytes migrating in  response  to 
mMCP-5 recombinant protein or to both chemokines (rmMCP-5 
protein and rmEotaxin protein) in peritoneal lavage fluid was de- 
termined as described before (10).  To determine the number of 
lymphocytes, monocytes,  and macrophages, slides were  stained 
with mAb against Thy 1.2  (53-2.1), Mac-1  (M1/70),  CD45R/ 
B220  (RA3-6B2)  from  PharMingen,  and  Moma-2  from  Bio- 
source International (Camanllo, CA) using an avidin/biotin staining 
method as described before and counterstained with hematoxylin. 
The  number  of leukocyte subtypes was  determined in  four 
high power fields (magnification of 400;  total area =  0.5  mm  2) 
per shde (duphcate slides per mouse and time point were exam- 
ined). Monocytes and macrophages were distinguished from lym- 
phocytes on the basis  of expression of Mac-1  and Moma-2  on 
their surface and from each other, based on the difference in size 
and  granularity observed after Giemsa counterstaining by light 
microscopy or by flow cytometry. 
Immunohistochemical Staining of Lungs and Lymphoid  Tissue for 
mMCP-5.  Sections of lungs from OVA-treated mice and of in- 
guinal LN  and thymi from  unchallenged mice were fixed and 
stained with an mAb directed against mMCP-5 using an avidin/ 
biotin staining method. Sections were overlaid with 20% normal 
rabbit serum in PBS for 15 rain. Lungs were incubated with neat 
anti-mMCP-5 (ZY2All) culture supernatant, and LN and thymi 
were incubated with anti-mMCP-5 ascites at 1/100, both over- 
night at  4°C.  Endogenous  peroxide was  subsequently blocked. 
Bound mAb was visualized by incubation with biotinylated rabbit 
anti-rat Ig diluted in  10% normal mouse serum PBS,  and then 
with streptavidin peroxidase complex prepared according to man- 
ufacturer's instructions (all from Dako), and incubated for 1 h. Fi- 
nally, the slides were flooded with peroxidase substrate solution 
before counterstaining with hematoxylin. Control sections were 
included  where  mAb,  biotinylated anti-rat  Ig,  or  streptavidin 
complex were  selectively omitted.  Control slides of lung were 
also  stained with an isotype-matched negative control antibody 
instead of primary antibody. 
Results 
Cloning,  Mapping,  and  Structural  Analysis  of mMCpo5. 
We  have  used  degenerated ohgonucleotides and  PCR  to 
clone novel CC chemokine cDNA sequences from RNAs 
extracted  from  eosinophilia  lungs  (10).  Three  distinct 
groups of 150-bp PCR products (including two degenerate 
primers) with different nucleotide sequences were obtained 
(10).  According to  the  sequence  from  one  of them,  one 
specific primer was designed to isolate the 5' partial cDNA 
by  5'  RACE  cloning strategy.  The  complete  cDNA  for 
this gene was then isolated by 3' RACE  cloning, which in- 
volved two further rounds of nested amphfication by PCR 
with primers based on the nucleotide sequence of the pre- 
viously cloned 5' fragment. 
The  cloned full-length cDNA for this novel gene  con- 
tains 540 bp, whose nucleotide sequence was confirmed by 
three independent PCR  amphfications. It includes an open 
reading  frame  of  341  bases  encoding  a  protein  of  104 
amino acids, a 5' untranslated region of 55 bp, and a 3' un- 
translated  region  of 145  bp  (data  not  shown.  GenBank/ 
EMBL/DDBJ  accession  number  U50712).  The  mature 
protein is composed of 82 amino acids containing five cys- 
teine residues (Fig. 1 A). No potential N-glycosylation sites 
are present in this protein. The nucleotide similarity of this 
gene with other CC chemokines is shown in Fig. 1 B. 
The comparison of the amino acid sequence of this novel 
gene  with  those  of other  members  of the  CC  chemokine 
family (Fig.  1 A)  revealed the highest similarity with  hu- 
man MCP-1  and MCP-3 (Fig. 1, A  and B). Because of this 
and  other features described below, this novel mouse  CC 
chemokine gene was named mouse monocyte chemotactic 
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Figure  1.  Companson of the 
armno  acid  sequence  of  the 
mMCP-5  mature  pepude  with 
that  of  other  CC  chemoklnes 
and  the  phylogeneuc  tree  of 
members of the CC  chemokine 
farmly, including  mMCP-5.  (A) 
An~no acid sequence  alignment 
of mMCP-5 with other human 
and mouse CC chemokines. The 
sequences were ahgned using the 
Clustal method with a PAM250 
residue weight table and default 
settings of gap penalties for pair- 
wise and multiple  ahguments  of 
3  and  10,  respectively  (Meg- 
Ahgn;  DNASTAR,  Inc.,  Madi- 
son, WI). Armno acid sequences 
of the  mature  proteins  for  the 
hMCP-1  (35), hMCP-2  (36), 
hMCP-3  (37), hMCP-4  (38), 
mMCP-1/JE  (39; 1-85  armno 
acids), and mEot (10) genes were 
compared to the armno acid se- 
quence  of the  putauve  mature 
mMCP-5  protem. Armno acids 
identical to mMCP-5 are shaded 
in black with numbers across the 
top  of the  sequence  referenced 
to  mMCP-5.  The  cDNA  se- 
quence  of mMCP-5  has  been 
deposited  in  GenBank/EMBL/ 
DDBJ under the accession num- 
ber  U50712.  (B)  Phylogeneuc 
tree of  the CC chemokine farmly 
includmg  mMCP-5  (bold  and 
underhned).  Distances to branch 
points are proportaonal to amino 
acid  sequence  divergence  from 
predicted  ancestral  sequences. 
Percent  sirmlanty  between  the 
nucleotide  sequence  of the cod- 
mg regaon or the amino acid se- 
quence of the mature  peptide of 
mMCP-5 and those of  other CC 
chemokanes  are  shown  at  the 
nght of the figure. 
protein-5.  Comparison of mMCP-5  mature peptide with 
hMCP-1 mature peptide or with the first 80 amino acids of 
the mMCP-1/JE mature peptide revealed 65 and 45% sim- 
ilarity, respectively (Fig.  1). mMCP-5 is a basic protein (10I 
9.07). The amino acid sequence phylogenetic tree and sim- 
ilarity comparisons with other CC chemokines  (Fig.  1 B) 
showed  that  mMCP-5  is  most similar and  evolutionarily 
related to hMCP-1. 
The mouse chromosomal location  of mMCP-5,  which 
was determined by interspecific back-cross analysis (22),  re- 
vealed that the single locus encoding for this cDNA is lo- 
cated in the central region of mouse chromosome 11  (data 
not shown). 
To determine the possible existence of a gene homolo- 
gous to  mMCP-5  in  humans,  a  southern  blot containing 
human  genomic DNA was hybridized with an mMCP-5 
cDNA probe. Under conditions of high stringency, a single 
hybridizing band was detected  (which had a different size 
from that found when the same blot was hybridized with 
an hMCP-1  probe; data not shown),  suggesting the exist- 
ence of an mMCP-5 homologue in humans. 
In  Vitro Chemotactic Responses of Leukocytes to mMCPo5. 
To  characterize the activities of mMCP-5  its expression in 
mammalian  cells was  engineered, as  we  have  done previ- 
ously (reference 10 and Materials and Methods). 
Eosinophil chemotaxis to mMCP-5  was examined using 
mouse eosinophils (90-95% pure) purified from the perito- 
neal cavity of IL-5-transgenic mice (23), since normal mice 
do  not  have  appreciable  numbers  of eosinophils.  Condi- 
tioned media containing mMCP-5  recombinant protein in- 
duced migration of eosinophils in a  dose-dependent man- 
ner compared to the control conditioned media (Fig. 2  A). 
In three independent experiments with different eosinophil 
and conditioned media preparations, recombinant mMCP-5 
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Migration (% of Control) 
Chemotactic activity of mMCP-5 on mouse leukocytes m vitro and neutralization of eosmophfl chemotaxas to mMCP-5 by anti-mMCP-5 
antibodies. (A) The indicated mouse leukocyte subtypes were subjected to chemotaxas to different diluuons of the conditioned media contalmng mMCP-5 
(solid  diamonds)  or of the control mock-conditioned media (empty  diamonds).  The bars and symbols show the mean and the range for one representative 
experiment out of three (or five for lymphocytes and monocytes). Results are expressed as chemotactic index (the ratio between the number of cells that 
magrated to the sample and the number that migrated to negative control, depicted as bars, axis on left of each plot) and magratlon (the percentage of the 
total number of input cells that migrated to the sample, depicted as lines, axis on the right of each plot). Positive controls (triangles) used for these expen- 
ments were rmEotaxin, rmMIP-lix, and rhlL-8. The migration ofleukocytes to assay media are also included (circle). In chemotaxis assays oflymphocytes 
to undiluted mMCP-5-contaming condmoned media (black bars) or undiluted control conditioned media (white bars), migratory cells were stained with 
anti-B220 or anti-Thy1.2 mAbs, and were analyzed by flow cytometry. (B) Eosinophil rmgration in response to rmMCP-5 is inhibited by specific Abs. 
The same chemotaxis assays described m A for eosinophils were performed. The mMCP-5-contammg or control conditioned media were premcubated 
with or without different concentrations ofpolyclonal antibodies agamst mMCP-5 (see Materials and Methods) or with rabbit Ig fraction as a control for 
15 min at 37°C and, then used for chemotaxis. The chemotaxls of eosmophils to Eotaxin in the presence of the same Abs was used as control for anti- 
MCP-5 Ab specificity. The percentage of migration observed m  the wells containing control supernatant and/or control Ab was subtracted from their 
corresponding experimental points. Data are expressed as the percentage of the posmve control (chemokine alone), which was considered 100%. 
from undiluted conditioned media attracted 10-19% of the 
input eosinophils in transwell chemotaxis assays. In parallel 
assays, only 1.1-2.3%  of input eosinophils migrated to the 
control conditioned media (Fig.  2  A).  Heparin/cation ex- 
change-purified protein (see Materials and Methods)  from 
mMCP-5--containing conditioned media induced  the  trans- 
migration of ~39%  (35-40% migration)  of eosinophil in- 
put (Fig.  2 A). 
To  evaluate  the  chemotactic  function  of mMCP-5  on 
lymphocytes,  four  independent  experiments  were  per- 
formed and showed that the conditioned media containing 
mMCP-5 induced the migration of lymphocytes from the 
bone  marrow  (Fig.  2  A)  and  from  the  peripheral  blood 
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(PB)  (data not shown and Fig. 2 A). We failed to detect re- 
producible chemotaxis of LN- or spleen-derived lympho- 
cytes to mMCP-5  (data not shown)  compared to the con- 
trol conditioned media, mMCP-5 attracted a subset (~2%) 
oflymphocytes from both the bone marrow and PB (Fig.  2 
A).  In a separate series of experiments, migratory lympho- 
cytes to  mMCP-5  were  stained with  either  anti-B220  or 
anti-Thyl  mAbs,  and  the  proportion  of positive cells  for 
each marker was analyzed by flow cytometry. B  lympho- 
cytes  displayed  a  stronger  response  to  mMCP-5  than  T 
lymphocytes, showing a higher chemotactic index (Fig. 2 A). 
Neutrophils  and  monocytes/macrophages  used  for  in 
vitro  chemotaxis  assays were  isolated  from  either  normal Eosinophils  Lymphocytes  Monocytes  Macrophages  Neutrophils 
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Figure 3.  mMCP-5 reduced recruitment ofleukocytes to the peritoneum. Peritoneal exudate was collected from C57BL/6J mice 2 h after injectmn of 
mMCP-5~containing conditioned media (closed  symbols) or control con&tinned media (open symbols). Each dot represents one mdividual mouse analyzed 
(10 mice per group). The bar in each panel represents the mean of  the total number of  cells of  the leukocyte subtype mdicated. For lymphocyte assays, B 
and T cells were also analyzed  separately by lmmunophenotypic analysis oflymphocytes recruited to the peritoneum after mMCP-5 mjectlon. 
mouse bone marrow (neutrophils or monocytes) after eryth- 
rocyte lysis  and Thyl  +  B220 lineage  depletion  from the 
peritoneal  cavities  of IL-5-transgenic  mice  (monocytes) 
after Gr-1  +  Thyl  +  B220 hneage depletion,  or from the 
peritoneum  of mice treated  previously with  thioglycollate 
(neutrophils  or monocytes).  Several separate  experiments 
(n =  9) with purified populations or enriched cell prepara- 
tions showed that mMCP-5-containing rather than control 
conditioned media ehcited concentration-dependent chemo- 
taxis  of monocytes  isolated  from  BM  (data  not  shown), 
from  the  peritoneum  of IL-5-transgenic  mice  (data  not 
shown), or from the peritoneal lavage of mice treated with 
thioglycollate (Fig.  2 A).  mMCP-5  supported  the chemo- 
tactic  migration  exclusively  of microscopically  small  and 
nongranular  monocytes that  clustered  in a  region  charac- 
terized by the lowest forward and right angle light scatters 
found  among monocytes  (defined  as  Mac1 +  Gr-1-;  data 
not shown) when analyzed by flow cytometry. No signifi- 
cant differences were found between mMCP-5-containing 
and control conditioned media in the  chemotactic migra- 
tion of neutrophils isolated either from bone marrow (Fig. 
2 A) or from the peritoneal cavity of thioglycollate-treated 
mice (not shown). These results were confirmed by the use 
of mMCP-5 purified by heparin/cation exchange chroma- 
tography in these assays, which showed similar chemotactic 
activity on lymphocytes and monocytes, but  not on neu- 
trophils (data not shown). 
To attribute  unequivocally all the  chemotactic activity 
to  eosinophils  present  in  the  conditioned  media  from 
mMCP-5-transfected  cells  to mMCP-5,  we blocked it in 
vitro with afl]mty-purified polyclonal antibodies raised against 
an  mMCP-5  peptide  (see  Materials  and  Methods).  Anti- 
mMCP-5  antibodies  were able to neutralize  almost all the 
eosinophil  chemotactic  activity  present  in  the  mMCP-5 
conditioned  media,  but  did  not  affect  the  chemotaxis  of 
eosinophils  to Eotaxin  (Fig.  2  B).  Similarly,  anti-MCP-5 
antibodies  were  able  to  neutralize  the  migration  of lym- 
phocytes and  monocytes to mMCP-5  in vitro  or in vivo 
(data not shown). 
In  Vivo  Peritoneal  Recruitment  of Leukocytes  to  mMCP-5. 
The injection of mMCP-5-containing conditioned media 
in mice resulted in a moderate increase in the total number 
of peritoneal  cells that maximized  (data not shown)  at 2  h 
after mMCP-5 recombinant protein injection (2.3  -+ 0.2 × 
106 cells/mouse)  when compared with the number of cells 
recovered from control mice injected with control condi- 
tioned media  (1.7  +  0.1  ×  106 cells/mouse)  or with PBS 
(1.5  --+ 0.3  X  106 cells/mouse).  In these experiments,  eosi- 
nophils increased from 0.25  -+ 0.13  X  10  s of the total cells 
in  the  peritoneal  exudate  of control  conditioned  media- 
injected mice or PBS-treated littermates to 2.1  +  0.6 X  105 in 
mMCP-5-containing conditioned media-injected mice. 
The injection  of mMCP-5  induced an increase  (,'-~l.4- 
fold)  in  peritoneal  lymphocytes that  was  not  observed  in 
control conditioned media-injected mice (Fig.  3).  mMCP-5 
injection  resulted  in an increase  in peritoneal  lymphocyte 
numbers caused by the predominant recruitment of B220 + 
B  lymphocytes (5.7  +  0.4  ×  105 cell/mouse  in mMCP- 
5-injected mice versus 4.4  +  0.1 x  105 cell/mouse in con- 
trol conditioned media-injected mice or 4.1  -+ 0.2  X  105 
cell/mouse  in  PBS-treated  mice;  Fig.  3).  The  number  of 
Thyl.2 +  T  lymphocytes  remained  comparable  in  these 
three  different  groups  of experimental  mice  at  the  same 
time point indicated  (5.8  +  2.3  ×  104; 4.9  +  1.5  X  104; 
and 5.1  +  1.2  ×  104 in mMCP-5-injected  mice,  control 
conditioned  media-injected  mice,  and  PBS-treated  mice, 
respectively; Fig. 3). 
No significant increases in the total number of neutrophils 
or macrophages recovered from the  exudates  of mMCP- 
5-injected mice were detected  at any time point analyzed 
(Fig. 3  and data not shown).  In contrast,  there were twice 
as many monocytes 2 h after mMCP-5 injection compared 
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Figure 4.  Expression of mMCP-5 under noninflammatory conditions. 
(A) Northern blot mMCP-5 cDNA with R.NA from different mouse or- 
gans. For confirmation ofmMCP-5 expression in some organs, two sepa- 
rately prepared P,.NAs from different mice were included m the Northern 
blot. The size of the hybridizing band is "-'0.5 kb. (B) Immunohtstochem- 
ical analysis of mMCP-5 expression in lymphoid organs. Inguinal LN (I 
and I/) and thyrm (III and IV) from nonimmunized mice were stained 
with  anti-mMCP-5  mAbs (//  and  IV)  or  with  an  irrelevant isotype- 
matched negauve control mAb (I and III). ×400.  C, cortex; M, medulla; 
P, paracortex; F, follicle. 
with that recovered from the exudate of mice injected with 
control conditioned media (Fig. 3). 
Pattern of Expression  of mMCP-5  under Noninflammatory 
Conditions.  Only  the  LN  and  thymus  expressed  consis- 
tently high levels ofmMCP-5  mRNA  ('~550 bp; Fig. 4 A). 
mMCP-5  mRNA  were also found in heart, skin, lung, and 
spleen by RT-PCR  (Fig.  4 A  and data not shown),  but no 
mMCP-5  mRNA  was  found  constitutively  in  any  other 
tissues of C57BL/6  mice (Fig. 4 A). 
To  determine  the  distribution  of mMCP-5  protein  in 
the LN and thymus,  immunohistochemical  analysis of sec- 
tions  from these  organs  was performed  after staining  with 
anti-mMCP-5  antibodies.  In  the  LN,  mMCP-5  staining 
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was  generally  localized  within  stromal-type  cells  in  the 
paracortex and primary follicles  (Fig.  4  B,  I/).  Few,  if any, 
lymphocytes  or  dendritic  cells  showed  immunoreactivity 
(Fig. 4  B and not shown).  In the thymus, stromal cells pre- 
dominantly present in the medulla reacted to the mMCP-5 
antibodies  (Fig.  4  B,  IV).  A  few  cells  in  the  cortex  were 
stained,  and  there  seemed  to  be  no  immunoreactive  thy- 
mocytes present (Fig. 4  B and data not shown).  No immu- 
noreactivity to any cell type was recognized in either tissue 
using other irrelevant isotype-matched mAbs ftom the  same 
hybridoma fusion (Fig.  4  B, I and III, and data not shown). 
Expression and Function of  mMCP-5 in the Lung during Allergic 
Inflammation.  Northern  analysis  showed  that  mMCP-5 
mR.NA  is markedly increased  in the lungs  of mice during 
the course of experimental lung eosinophilia  (Fig. 5 A), us- 
ing  repeated  doses  of  aerosolized  OVA  for  21  d  (10). 
mMCP-5  mRNA  expression,  which was expressed at very 
low levels in the  lung of unmanipulated  mice, peaked 3  h 
after  OVA  challenge  on  the  days  analyzed  (Fig.  5  A  and 
data  not  shown),  thus  coinciding  with  the  time  point  of 
maximal eosinophil  accumulation  on  these  days (10).  Fur- 
thermore,  mMCP-5  protein  was  localized  by  immuno- 
staining  to  alveolar  macrophages  and  to  smooth  muscle 
cells most strongly (Fig. 5 B). A small number ofleukocytes 
within  the large perivascular and peribronchiolar  infiltrates 
showed  low  immunoreactivity  (Fig.  5  B  and  data  not 
shown).  In areas of leukocyte localization in the lung tissue, 
there  was  an  increase  in  reactivities  of  macrophages, 
smooth muscle cells, and other tissue resident cells that cor- 
related with the severity of the infiltrate  (not shown). 
To evaluate the  contribution  of mMCP-5  to the devel- 
opment of OVA-induced  lung  eosinophilia,  anti-mMCP-5 
neutralizing  Abs  were  administered  30  min  before  OVA 
challenge  at the  time of maximal eosinophil  accumulation 
(days  20  and  21  of treatment).  This  antibody  preparation 
was  shown  to  block  the  transmigration  of eosinophils  to 
mMCP-5  in  vitro  (Fig.  2  B).  Our  results  showed  that 
blocking ofmMCP-5  in vivo reduced by "-~25% the num- 
ber of eosinophils  that accumulated in the BAL after OVA 
c~rallenge at the same time point indicated  (Fig.  5  C). 
Regulation  of mMCPo5  Expression In  Vivo and  In  Vitro. 
Based  on  our  previous  finding  (11)  that  the  presence  of 
lymphocytes is absolutely required  for eosinophil  accumu- 
lation in this model, we studied the regulation of mMCP-5 
mRNA  expression  in  the  lungs  of lymphocyte-deficient 
RAG-1  mutant  mice  (24).  Fig.  6  A  shows  that  there  was 
strong reduction  in the levels of mMCP-5  mRNA  on days 
15  and  18  in  OVA-treated  RAG-1  mice when  compared 
with  OVA-treated  wild-type  controls.  It also  revealed  on 
day  21  a  moderate,  but  notable,  reduction  in  the  level  of 
expression  of  mMCP-5  in  the  lungs  of  OVA-treated 
RAG-l-deficient  mice  (n  =  3;  Fig.  6  A).  In  contrast,  a 
comparable level ofmRNA  expression ofEotaxin, R.ANTES, 
and  MIP-lo~  was  found  in  the  lung  of mutant  and  wild- 
type control mice at each point during the OVA treatment 
(Fig. 6 A). 
To  investigate  which  lymphocyte  subtype(s)  could  be 
involved in the regulation  of mMCP-5  expression,  North- A 
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Figure  5.  Expression  and  fianction 
of mMCP-5  mRNA  during  OVA- 
induced  lung  allergic  inflammation. 
(A) At the different  time points  indi- 
cated atier OVA administration, North- 
em blot analysis was performed to de- 
termine the expression of chemokines 
m the lung. (B) Expression ofmMCP-5 
protein  in  lungs  from  OVA-treated 
mice.  Immunobastochermcal  analysis 
was  performed upon  lung tissue iso- 
lated on day 21 of OVA treatment  us- 
ing  monoclonal  anti-mMCP-5  (see 
Matenals  and  Methods).  Alveolar 
macrophages were prominently  stained 
m  OVA-treated  mice  (arrows),  and 
smooth muscle cells (arrowheads) of the 
bronchioles  were also densely stained 
m  treated  but  not  untreated  mace. 
(×1,000).  (C)  Blocking of mMCP-5 
protein with specific neutralizing anta- 
bodies  (as used m  Fig. 2 B) dunng the 
course of OVA-induced allergic mflam- 
marion  (see Materials  and  Methods). 
Bronchoalveolar  lavage was  recovered 
from a treated mouse,  and  eosmophds 
were enumerated.  Each dot represents 
a single mouse. 
ern analysis was performed using RNAs  from the lungs  of 
mice  lacking  either  T  and  NK  cells  (CD3~-transgenic 
mice;  14)  or  CD4 +  T  cells  (CD4-deficient  mice;  25)  or 
CD8 +  T  cells  (CD8-deficient  mice;  26)  after  OVA  treat- 
ment.  We  found  a  comparable  level of mMCP-5  mRNA 
expression  in  the  lungs  of  these  immunodeficient  mice 
when compared with that observed in wild-type littermates 
during OVA  treatment  (Fig. 6  A  and data not shown). 
To address the regulation of mMCP-5  expression in dif- 
ferent lung resident  cell types present  during  allergic eosi- 
nophilia, we evaluated the presence of mRNA  for mMCP-5 
in  a  panel  of unstimulated  and  stimulated  cell lines  and  in 
1946  mMCP-5 in Lung Allergic Inflammation freshly isolated cells of different lineages by RT-PCR  (Fig. 
6/3)  or Northern blotting (data not shown). We compared 
this regulation with that of Eotaxin, whose  strong and in- 
ducible mRNA  expression was found not to be reduced in 
lymphocyte-deficient mice during OVA treatment (Fig. 6 A). 
No  expression  of  mMCP-5  mP,  NA  was  found  on 
freshly isolated peritoneal macrophages by lkT-PCI<  (Fig. 
6  /3).  When  macrophages  were  stimulated  in  vitro  with 
IFN-'y,  but  not  with  TNF-o~,  however,  they  expressed 
mMCP-5  mRNA  at  an  easily detectable level  (F~g.  6  /3). 
Conversely, the same population of freshly isolated perito- 
neal  macrophages  stimulated  with  TNF-oL,  but  not  with 
IFN-y, expressed mP,.NA for mEotaxin  (Fig. 6/3).  Similar 
results were obtained when two macrophage cell lines were 
analyzed  (Fig.  6  /3).  mMCP-5  mP,.NA  expression  was 
found  in  unstimulated  or  LPS-stimulated  P388D1  mac- 
rophages, but not in RAW287  cells (Fig. 6/3).  In contrast, 
only RAW287  cells expressed detectable mRNA  levels of 
mEotaxin. 
A  day 15  day  18  day 21 
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Figure  6.  Regulation  of mMCP-5  nfl~NA  expression In  VlVO and m 
vitro  (A)  Expression ofmMCP-5  mRNA  in the lungs of RAG-l-defi- 
cmnt n-nce and CD3e-transgenlc mice dunng lung allergic inflammation. 
Northern  blot analysis was perfomled using total RNAs from lungs 3 h 
after OVA ad~mmstratlon on days 15,  18, and 21  of the treatment  Ex- 
presslon of two representanve wild-type mice out of five at each time 
point,  two out of five RAG-l-deficient mice on  days 15 and  18,  and 
three out of five RAG-l-deficient  rmce on day 21, as well as one CD3e- 
transgenic mouse on days 15 and 21, and two on day 18 is shown. (B) 
Comparison of the mRNA expression pattern of  the mMCP-5 and mEo- 
taxln genes in different cell lines and freshly isolated cells. Total R.NA 
from cells indicated rather without  stlmulatmn (-) or after exposure to 
&fferent stimuli (+, see Materials and Methods) was amplified by RT- 
PCR with  in&vldual gene-specific pnmers. Either  [3-actln or GAPDH 
was used as the control for these experiments. 
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mMCP-5  mRNA  was  also  found  to  be  expressed  by 
BMCMC  and in the mast cell line C1MC/C57.1.  In con- 
trast,  no  mEotaxin  mlKNA was  found  in  these  two  mast 
cell populations,  either resting (Fig. 6  B  and reference  10) 
or after stimulation with IgE and antigen (data not shown). 
Low but detectable levels of mMCP-5  mlKNA were ob- 
served in the endothelial cell hne b-End2 with or without 
stimuli  (Fig.  6  B),  whereas  no  mMCP-5  mRNA  was  de- 
tected in nonstimulated or LPS-stimulated NIH3T3  fibro- 
blasts (Fig. 6  B).  In contrast, both cell lines express detect- 
able levels of mEotaxin mlKNA. 
Role  of mMCP5  in  mEotaxin-induced  Eosinophil  Recruit- 
merit In  Viuo and In  Vitro.  To  examine whether  the  pres- 
ence  of mMCP-5  in  the  eosmophlhc lung,  m  which  Eo- 
taxin is abundantly expressed, could lead either to a  larger 
accumulation  of eosinophils or is a  possible mechanism  to 
control the inflammatory response, Eotaxin  (0.5  bLg/mouse) 
was  coinjected  in  the  peritoneum  either  with  400  lxl/ 
mouse  (Fig.  7  A)  or  800  Ixl/mouse  (data  not  shown)  of 
conditioned media containing mMCP-5  recombinant pro- 
tein or with the  same volumes of the  control conditioned 
media.  The  total number  of peritoneal eosinophils recov- 
ered from mMCP-5-injected mice or from Eotaxin-injected 
mice 2 h afeer injection was 2.2  +  0.6 X  105 and 1.3 +  0.5 X 
105 cells/mouse, respectively (Fig. 7 A). When both chemo- 
kines were administered simultaneously, the number of in- 
filtrating  eosinophlls  was  lower  (0.8  +  0.3  ×  105  cells/ 
mouse,  Fig. 7 A) than that found in the peritoneal exudate 
of m~ce injected with  either one  alone.  In contrast,  when 
m/VlCP-5 and mEotaxin were administered simultaneously 
at  very low  doses  (100  and  0.2  Ixg/mouse,  respectively), 
the  number  of infiltrating eosinophils  (0.5  +  0.18  ×  10 s 
cells/mouse) was greater than those found when mMCP-5 
or mEotaxin  were  injected individually at  the  same  doses 
(0.09  --- 0.01  ×  105  cells/mouse for mMCP-5  and 0.2  + 
0.03  X  105 cells/mouse for mEotaxin; Fig. 7 A). 
To  further  define the  chemotactic  responses  of eosino- 
phils to  combinations of mMCP-5  and mEotaxin,  we ex- 
amined them in vitro. The results from two individual ex- 
periments representative of this experimental series (n  =  5) 
are shown  in  Fig. 7  B.  mMCP-5  enhanced  the  migration 
of eosinophils to mEotaxin  (from 3  to  10% in the presence 
of &fferent  concentration  of mEotaxin).  The  maximum 
enhancement  was  reproducibly observed when  10  ng/ml 
of mEotaxin was combined with undiluted mMCP-5  con- 
ditioned media  (Fig.  7  B).  As  the  concentration  of mEot 
was increased from  10  to  250  ng/ml m  combination with 
undiluted mMCP-5-containing  conditioned media in  the 
different  experiments,  eosmophil migration was  enhanced 
to  a  lesser  extent,  until  no  mMCP-5-induced  enhance- 
ment  of eosinophil chemotaxis was  seen  at  250  ng/ml  of 
mEotaxin  (Fig. 7  /3).  Furthermore,  mMCP-5  reduced the 
mEotaxin-mduced eosinophil transmigranon in vitro when 
combined with a high concentranon ofmEotaxin (from 50 
to  250  ng/ml,  depending on  the  experiment).  This  effect 
was not observed when the control conditioned media was 
combined with different concentrations ofmEotaxin in the 
same experiments (Fig. 7  B). We have selected two experi- A  , 
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Figure 7.  Effect of mMCP-5 on mEotaxm-lnduced eoslnophll migra- 
tion in VlVO and m vitro. (A) Pentoneal eosmophil  accumulation  in re- 
sponse to mMCP-5 and mEotaxm comjection.  The number of eoslno- 
phlls m the pentoneal exudate of C57BL/6J mice 2 h after Injection with 
mMCP-5 (open circles), mEotaxln (open squares), or both chemokines  si- 
multaneously  (closed circles) was determined  as described in Materials and 
Methods. Values shown in the left panel reflect the number ofeosmophils 
recovered from the peritoneal exudates of mice injected with 400 ~l/mouse 
of mMCP-5-containmg  conditioned  media  and/or  0.5  p~g/mouse of 
mEotaxm m  400  Ixl PBS, whereas  values shown  in the right  panel  are 
from mice injected  with 100 jxl/mouse  of mMCP-5-contalmng condi- 
tioned media and/or 0 2 ~tg/mouse ofmEotaxm m 400 pA of PBS. Con- 
trol mice (x) rejected with the same volume of control conditioned media 
and/or 400  Ixl/mouse  of PBS (n =  4). Mice injected with Eotaxln (but 
not with MCP-5) were comjected also with the same volume of control 
conditioned media. The bars m each panel represent the mean of the total 
number of eosmophlls recovered from the mice analyzed  (each symbol 
represents one individual mouse).  (/3) Eoslnophll  chemotaxis in response 
to combinations  of mMCP-5 and mEotaxm in vitro in the transwell rm- 
gration assay. Two independent expenments  out of five are shown.  The 
ments  to  illustrate  that  we  did  observe  donor-to-donor 
variation  in  the  relative responses  to  mMCP-5  and  mEo- 
taxin, although the pattern discussed above was maintained. 
Discussion 
We have identified a novel mouse CC  chemokme that is 
chemotactic  for  eosinophils,  monocytes,  and  lymphocytes 
from the lung of mice during an allergic inflammatory  re- 
sponse characterized by eosinophilic infiltration. Because of 
its  polyspecificity,  its  differential  gene  regulation,  and  its 
modulatory  effect  on  action  of Eotaxin,  we  propose  that 
mMCP-5  plays  a  pivotal role  during  lung allergic inflam- 
mation. 
mMCP-5 Is a Novel C-C Chemokine Closely related  to Hu- 
man MCP-1.  The  amino  acid  sequence  of mMCP-5  is 
very similar to  that  of members  of the  human  MCP  sub- 
branch  (27).  The first amino acid in the mature protein that 
has been shown to be critical for MCP  functions  (28)  is not 
conserved between mMCP-5  and hMCPs.  Moreover, com- 
pared  to  three  human  MCPs,  mMCP-5  has  the  longer 
peptide and has an additional cysteine at the COOH  termi- 
nus,  which  might  form  an  additional  disulphide  bond  in 
the  protein.  It  also  has  a  lower theoretical pI  than  that  of 
MCPs  (27).  mMCP-5  is  very  similar  to  hMCP-1  (65%), 
yet is quite different from mMCP-1/JE  (45%) and from the 
recently described hMCP-4  (,'-~51%;  Fig.  1).  Three reasons 
lead us to postulate  that mMCP-5  is not the mouse homo- 
logue ofhMCP-l:  (a)  the moderate monocyte chemotactic 
activity of low concentrations  of mMCP-5,  and  its potent 
activity on  eosinophils,  which  is  different from  the  activi- 
ties reported for hMCP-1  (29);  (b)  the observation that m  a 
cross-species  Southern  blot  with  hMCP-1  and  mMCP-1 
probes,  the same band  is recognized  (Rollins,  B.,  personal 
communication);  and  (c)  our  preliminary  observation  that 
under  conditions  of high  stringency,  a  single  band  is  de- 
tected when  an mMCP-5  probe  is hybridized to  a  South- 
ern  blot  containing  human  genomic  DNA  (experiments 
are  underway  in  our  laboratory  to  clone  the  full-length 
cDNA  of this putative mMCP-5  homologue in humans). 
mMCP-5  Is  a  Chemotactic  Factor for  Monocytes,  Lympho- 
cytes, and Eosinophils In  Vitro and In  Vivo.  In  this  study,  we 
demonstrate  that  mMCP-5  induces  the  chemotactic  trans- 
migration  of monocytes,  lymphocytes,  and  eosinophils  in 
percentage  of input cells that rmgrated was measured. Each experimental 
point was tested in duplicate.  As a control,  the undiluted  mock-condi- 
tioned media  was mixed with different  concentrations  of mEotaxm m 
parallel and used m the same assays. The upper panel represents the raw 
data of two representauve  expenments  out of five that were performed. 
Mlgrauon  is  expressed  as  mean  values  and  bars show  duplicates.  The 
lower panel represents the net difference between the mlgrauon (percent- 
age of input) ofeoslnophds to different concentrauons  ofmEotaxm in the 
presence or absence of mMCP-5 (as shown m the upper panel). The val- 
ues were calculated by subtracting  (individually for each concentration  of 
Eotaxan used) the percentage  of eosmophil  migration  induced by mEo- 
taxln in the absence of mMCP-5 (but with the same volume of control 
condmoned media) from the percentage ofeoslnophd migration reduced 
by mEotaxm m the presence ofmMCP-5. 
1948  m/VICP-5 in Lung Allergic Inflammation vitro, but that it has  no effect on the  chemotaxis of neu- 
trophils  (Fig.  2  A).  While  mMCP-5  induced  significant 
chemotaxis  of these  three  leukocyte  subsets,  eosinophils 
exhibited  the  greatest  response.  This  response  could  be 
completely blocked by  antibodies  against  mMCP-5.  Al- 
though the migratory response to mMCP-5  in monocyte 
or lymphocyte populations was low (1.5-2%), the chemo- 
tactic index of these cell types was comparable to that found 
in these cell types to other chemoattractants, such as MIP-lot 
or R_ANTES (30). Among lymphocytes, B cells responded 
to mMCP-5  better than T  cells did. mMCP-5 is the only 
mouse CC chemokine reported to date that promotes the 
chemotactic migration ofB lymphocytes, although hMIP-loL 
has been reported to be chemotactic for human B lympho- 
cytes (31).  The differential response of lymphocytes from 
different hemotapoietic organs to  mMCP-5  is  intriguing, 
and may reflect intrinsic  differences in  the migratory be- 
havior oflymphocytes from distinct locations. In vivo stud- 
ies  showed that mMCP-5  was  also  effective in recruiting 
leukocytes to the peritoneum after challenge (Fig. 3). 
Stromal Cells in the LN and  Thymus Express Constitutively 
mMCP-5.  The LN is a highly organized lymphoid tissue 
in which  different leukocyte subsets  and stromal cells  ar- 
range themselves into specialized compartments to which 
particular subsets  of lymphocytes migrate in a very specific 
fashion (32, 33). In the thymus, mature and immature thy- 
mocytes interact with stromal cells,  and these interactions 
are critical for their maturation.  The constitutive mRNA 
expression of mMCP-5  in the LN and thymus (Fig.  4 B), 
together  with  its  chemotactic  activity  on  lymphocytes, 
make  it  an  interesting  candidate  for participation  in  this 
process, mMCP-5 does not support T  nor B cell prolifera- 
tion in vitro  (data  not  shown).  It is  notable that  we  de- 
tected mRNA  for mMCP-5  in  both skeletal and  cardiac 
muscles  (Fig.  4  A).  We  also  found  expression  in  heart, 
lung, and skin, but there was great variability between the 
mice that were studied. 
mMCP-5 Is Different  from the Other Major CC Chemokines 
in That Its Expression during Allergic Inflammation Is Critically 
Regulated by Lymphocytes.  We show here that the expres- 
sion of mMCP-5 mRNA in the lung is maximal 3 h  after 
OVA challenge on all days analyzed during OVA treatment 
(days 15, 18, and 21). However, a clear increase in mMCP-5 
mRNA  levels was  not  seen  as  treatment  progressed.  In- 
stead, the levels for mMCP-5 mRNA were almost constant 
3  h  after challenge at all time points analyzed (Fig.  5 A), 
contrasting with other CC chemokines in this model (10). 
The pattern of mRNA mMCP-5 expression might reflect: 
(a)  its  polyspecificity, and  thus  it is  conceivable that  this 
chemokine could be involved in the recruitment ofmono- 
cytes (which accumulate in the lung at maximum levels on 
day 15) and of eosinophils and/or lymphocytes (which ac- 
cumulate in the lung at maximum levels on day 21) during 
the allergic process induced by the OVA treatment (10); or 
(b) different activation signals inducing chemokine expres- 
sion  in  different  cell  types,  for  example,  in  mast  cells, 
mMCP-5  is  readily  expressed,  whereas  Eotaxin  is  not. 
Blocking the mMCP-5  protein with specific antibodies in 
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vivo during the induction of lung eosinophilia resulted in a 
significant  decrease  (N25%,  P  <0.05)  in  the  number  of 
eosinophils that accumulated in the lung. These resnlts  in- 
dicate  that  mMCP-5  contributes  either  directly or indi- 
rectly  to  the  development  of lung  eosinophilia  in  this 
model.  Although  other  eosinophilic  chemokines  are  ex- 
pressed during the course of the OVA treatment (Fig. 6 A), 
m_MCP-5 and RANTES are the predominant ones at ear- 
lier points of this particular inflammatory response (day 15). 
Accordingly, on day 15 of the OVA treatment, the block- 
age of mMCP-5  with Ab revealed that at this time point, 
thzs chemokine is responsible for 80% of the accumulation 
of eosinophils in the lung (Gonzalo, J.A., and J.C. Gutier- 
rez-Ramos, unpubhshed data). 
Analysis  of lung tissue  from mice that were exposed to 
OVA (day 21, 3 h after challenge) revealed intense staining 
of alveolar macrophages and smooth muscle cells (Fig. 5 B) 
and much less intense staining of epithelial and possibly en- 
dothelial  cells  and  fibroblasts  (Fig.  5  B),  which  are  well 
characterized for their ability to produce other chemokines, 
such  as  MCP-1  and  MIP-1  (34).  It is  notable,  however, 
that the cell type primarily responsible for Eotaxin produc- 
tion is the alveolar epithelium (10,  11). We failed to deter- 
mine by immunostaining if mast cells have MCP-5 immu- 
noreactivity in vivo. 
A hallmark of mMCP-5, which distinguishes it from the 
other CC chemokines present in the eosinophilic lung, is its 
differential mRNA regulation during lung allergic inflam- 
mation.  Only  mMCP-5  mRNA  expression  was  signifi- 
cantly reduced in the lung of OVA-treated, RAG-1  mu- 
tant mice (Fig. 6 A). This suggests that lymphocytes play an 
important role in the expression of mMCP-5 during aller- 
gic inflammation. Furthermore, similar levels of expression 
of mMCP-5 mRNA in the lungs of mutant mice lacking 
T  cells  (CD3e-transgenlc  mice,  CD4-deficient mice, and 
CD8-deficient mice) and wild-type littermates during OVA 
treatment demonstrate that B lymphocytes (P,.AG-l~teficient 
mice)  but  not  T  lymphocytes are  essential  for mMCP-5 
expression (Fig. 6 A and data not shown). 
It should be emphasized that no mMCP-5 immunoreac- 
tivity was found in infiltrating leukocytes in lung sections 
of OVA-treated mice (Fig. 5 B), and therefore it is unlikely 
that the strong reduction in mMCP-5 mRNA levels in the 
lung of OVA-treated, RAG-l-deficient mice could be at- 
tributed directly to the absence of few, if any, mMCP- 
5-expressing lymphocytes. Rather, we favor the hypothesis 
that B lymphocytes deliver key signals to induce mMCP5 
expression by macrophages,  smooth  muscle  cells,  and/or 
other tissue  resident cell types. This allows the hypothesis 
that regulation of the expression of mMCP-5  and of, for 
example, Eotaxin might be governed by different signals. 
Correspondingly, we found almost opposite patterns of ex- 
pression for Eotaxin and mMCP5 mRNAs after activation 
of  primary cultures ofmacrophages or mast cells (mMCP-5 
mRNA can be produced by the mast cells studied here, but 
not Eotaxin mRNA  [Fig.  6  B and reference 10]).  More- 
over, different mMCP-5 and mEotaxin mlLNA expression 
was found in various cell lines representing some of the cell lineages  that  may  produce  mMCP5  in  the  inflamed  lung 
(Fig. 6/3). 
The  Migration  of Eosinophils  to  Eotaxin  Is  Modulated  by 
mMCP-5 In  Vivo and h~  Vitro.  Our results demonstrate that 
doses  of either  mMCP-5  or  mEotaxin,  which  by  them- 
selves  are  each  able  to  induce  a  significant  increase  m  the 
number of infiltrating eosinophils, fail to exert the same ef- 
fect when  coinjected  (Fig.  7  A).  In contrast,  doses of both 
chemokines  that  separately  elicit  a  small  but  significant 
peritoneal recruitment of eosinophils showed a cooperative 
effect in  the recrultment  of eosinophils when  simultaneously 
injected  (Fig.  7  A).  Mso in vitro,  our results showed that a 
constant  amount  of mMCP-5  can  either  enhance  or  re- 
duce  the  chemotaxis of eosinophils  to  Eotaxin.  Therefore, 
mMCP-5  modified the bell-shape curve of the response to 
Eotaxin  (Fig.  7  /3).  These  results  suggest  that  mMCP-5 
would cooperate with low amounts of Eotaxin in augmenting 
the directed movement of eosinophils in the chemotaxis as- 
say.  When  a  certain  concentration  of Eotaxin  is reached  in 
the  assay,  however,  the  presence  of mMCP-5  reduces  the 
response to Eotaxin. Experiments are underway to determine 
if MCP-5  and Eotaxin share a receptor on eosinophils. 
Our initial work on the novel chemokine mMCP-5  has 
focused  on  the  characterization  of its  possible  function  in 
allergic  inflammatory  reaction  situations.  The  expression 
and function  of mMCP-5  have  unique  characteristics  dur- 
ing lung allergic inflammation that distinguish it from other 
CC chemokines studied. 
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